drugset / Trial / NCT00171574
Antiproteinuric Effect of Valsartan and Lisinopril
RandomizedParallel-groupDouble-blindTreatment
Summary
Title: Antiproteinuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), double blind, parallel group, controlled trial, 5 months follow-up. Objective: To evaluate the antiproteinuric effect of high doses of valsartan vs combo treatment in no-diabetic and diabetic patients. Hypothesis: Combo treatment reduces microalbuminuria, proteinuria and the albumin/creatinin ratio more than monotherapies. Design: Multicentric, randomized, double blind, parallel group, active controlled. Dose / regimen Valsartan 320 vs Lisinopril 40 vs Valsartan/lisinopril 160/20
Timeline
- Start
- 2004-11
- Primary completion
- 2006-07
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 20 mg | — |
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 40 mg | — |
| Subject | Valsartan | Small molecule | 160 mg | — |
| Subject | Valsartan | Small molecule | 320 mg | — |
| Background | Hydrochlorothiazide | Unknown | — | — |